



(12) Patent specification

(10) SE 539 450 C2

(21) Patent application number:	1650260-1	(51) Int.Cl.:	
(45) Grant of patent:	2017-09-26	<b>A61K 31/506</b>	(2006.01)
(41) Available to the public:	2017-08-30	<b>A61P 9/00</b>	(2006.01)
(22) Filing date:	2016-02-29		
(24) Effective date:	2016-02-29		
(30) Priority data:	---		

(73) Patentee: Hamra Invest AB, Hågervägen 27, 746 34 Bålsta SE  
Brain consultant Nils Gunnar Wahlgren AB, Sagostigen 8, 167 54 Bromma SE

(72) Inventor: Ulf Eriksson, Bålsta SE  
Nils Gunnar Wahlgren, Bromma SE

(74) Agent: KRANSELL & WENNBORG KB, Box 27834, 115 93, Stockholm SE

(54) Title: Imatinib for use in the treatment of stroke

(56) Cited documents: WO 2006121941 A2 · US 20090264438 A1

(57) Abstract:

Imatinib can be used in the treatment of stroke in a new dosage regime, where Imatinib is administered to the patient at a dose of 650 mg/day or higher for at least 3 consecutive days, and preferably administered in a starting dose of 1000 mg/day or higher on day 1, and at a dose in the interval of 650 mg/day to 1000 mg/day on the subsequent days. A method for the treatment of stroke, a pharmaceutical composition and a kit of parts is/are also disclosed.